The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin

Cancer Res. 2003 Jan 15;63(2):382-5.

Abstract

Recently, we demonstrated that the designed peptide anginex displays potent antiangiogenic activity. The aim of the present study was to investigate anginex treatment as a single-agent therapy and to test its ability to improve conventional chemotherapy and antiangiogenesis therapy. In a human ovarian carcinoma mouse model, anginex inhibited tumor growth by 70%. When anginex was combined with a suboptimal dose of carboplatin, tumors regressed to an impalpable state. Anginex plus angiostatin worked synergistically to inhibit tumor growth. Assessment of microvessel density suggested that the antitumor activity of anginex is mediated by angiogenesis inhibition. In any of the experiments, no sign of anginex-induced toxicity was observed.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / pharmacology*
  • Angiostatins
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Carboplatin / administration & dosage
  • Cell Division / drug effects
  • Drug Synergism
  • Female
  • Humans
  • Mice
  • Mice, Nude
  • Neovascularization, Pathologic / drug therapy*
  • Ovarian Neoplasms / blood supply
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / pathology
  • Peptide Fragments / administration & dosage
  • Peptides
  • Plasminogen / administration & dosage
  • Proteins / administration & dosage
  • Proteins / adverse effects
  • Proteins / pharmacology*
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays

Substances

  • Angiogenesis Inhibitors
  • Peptide Fragments
  • Peptides
  • Proteins
  • betapep-25 protein, synthetic
  • Angiostatins
  • Plasminogen
  • Carboplatin